All articles by Vishnu Priyan

MHLW accepts GSK’s multiple myeloma treatment NDA for review

Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted for review GSK's new drug application (NDA) for Blenrep (belantamab…
Orbis and Vivtex partner to develop oral macrocycle drugs

Orbis Medicines has announced a research collaboration and an option to an exclusive licence to Vivtex to support the development…
BeiGene’s TEVIMBRA gains approval for OSCC in Israel

The Israeli Ministry of Health (IL MOH) has approved BeiGene’s TEVIMBRA (tislelizumab) as a monotherapy to treat adults with unresectable…
Nura Bio secures funding to advance neuroprotective therapies

Nura Bio has secured an additional $68m in a Series A financing round to advance the development of its neuroprotective…
Sobi and Enable Injections partner for Aspaveli distribution

Swedish Orphan Biovitrum (Sobi) and Enable Injections have entered a global agreement to develop and distribute Aspaveli (pegcetacoplan) in combination…

FDA approves Roche’s Tecentriq Hybreza for cancer

The US Food and Drug Administration (FDA) has approved Roche's Tecentriq Hybreza, a subcutaneous anti-PD-(L)1 cancer immunotherapy. The treatment offers…
Sanofi signs radioligand therapy licensing deal for rare cancers

Sanofi has signed an exclusive licensing agreement with RadioMedix and Orano Med to advance the radioligand therapy AlphaMedix for rare…
Eli Lilly to invest $1.8bn in manufacturing capacity in Ireland

Eli Lilly and Company has announced a significant expansion of its manufacturing presence in Ireland, with a $1bn investment earmarked…
Agios Pharmaceuticals’ tebapivat gains FDA orphan drug designation

Agios Pharmaceuticals has announced that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to tebapivat (AG-946)…
India’s CDSCO suspends Entod’s licence for PresVu eye drops

Due to safety concerns and unauthorised claims, the Central Drugs Standard Control Organisation (CDSCO) of India has suspended the manufacturing…